This content is from: Premium Viking Leads Tiger-Related Funds in Latest Biopharma IPO Viking and Matrix Capital Management are the largest outside investors in Adaptive Biotechnologies. By Stephen Taub June 02, 2019
This content is from: Premium Perceptive Advisors Posts Best Results Since 2000, Gaining 54% The life sciences firm is also raising money for a new credit fund. By Stephen Taub January 15, 2020
This content is from: Premium Perceptive Anticipates Another IPO SpringWorks Therapeutics is the fifth company in the hedge fund’s private portfolio to go public this year. Not all of them have worked out so far. By Stephen Taub August 23, 2019
This content is from: Premium Biotech IPOs Are a Mixed Bag for Hedge Funds A recent spate of biotech company IPOs has yielded some early winners and losers. By Stephen Taub July 24, 2019
This content is from: Premium EcoR1 Puts Up Big Gains as the Hedge Fund Scoops Up Biotech EcoR1’s main hedge fund has produced big, double-digit gains in 2019, according to a document obtained by Institutional Investor. By Steve Taub December 22, 2019
This content is from: Premium Viking’s Hybrid Fund Surges on Private Investments The fund, which invests in a mix of private and public funds, is way outpacing its better-known siblings. By Stephen Taub October 08, 2019
Sponsored The Small Cap Opportunity in Emerging Markets Sponsored by Mackenzie Investments February 27, 2020
Sponsored Special Report: Emerging Markets: Adding Value Through a Disciplined Strategy Sponsored by Mackenzie Investments February 27, 2020
